Physician profile
Frederic J Simmons
NPI 1952318750
$1,734.85
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $699 · 2020: $456 · 2021: $528 · 2022: $52.21.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $514.32 | 2019-2022 | |
| Amarin Pharma, INC. | $372.81 | 2019-2022 | |
| Lilly USA, LLC | $232.79 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $150.68 | 2019-2021 | |
| Eisai INC. | $92.62 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $90.45 | 2019 | |
| Pfizer INC. | $82.15 | 2019-2021 | |
| Abbott Laboratories | $44.33 | 2020-2021 | |
| Abbvie INC. | $33.10 | 2021 | |
| Janssen Pharmaceuticals, INC | $29.43 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $29.37 | 2021-2022 | |
| Almatica Pharma LLC | $23.94 | 2021 | |
| Allergan, INC. | $13.39 | 2020 | |
| Merck Sharp & Dohme LLC | $12.98 | 2019 | |
| Amgen INC. | $12.49 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederic Simmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.